FibroGen, Inc. (NASDAQ:FGEN) Files An 8-K Other Events

Item8.01. Other Events.

On April5, 2017, FibroGen, Inc. (the Registrant) entered into an
underwriting agreement with Leerink Partners LLC and Stifel,
Nicolaus Company, Incorporated, relating to the issuance and sale
of 5,228,750 shares of the Registrants common stock (the
Offering) at a price to the public of $22.95 per share. The gross
proceeds to the Registrant from the Offering are expected to be
$120.0million before deducting the underwriting discounts and
commissions and offering expenses payable by the Registrant. The
offering is scheduled to close on or about April11, 2017, subject
to customary closing conditions.

The underwriting agreement contains customary representations,
warranties, covenants and agreements by the Registrant,
indemnification obligations of the Registrant and the
underwriters, including for liabilities under the Securities Act
of 1933, as amended, other obligations of the parties and
termination provisions. The representations, warranties and
covenants contained in the underwriting agreement were made only
for purposes of such agreement and as of specific dates, were
solely for the benefit of the parties to the underwriting
agreement, and may be subject to limitations agreed upon by the
contracting parties.

The Offering is being made by means of a written prospectus
supplement and accompanying prospectus forming part of a shelf
registration statement on Form S-3 (Registration Statement
No.333-216368), previously filed with the Securities and Exchange
Commission (SEC) and declared effective by the SEC on March1,
2017.

The underwriting agreement is attached as Exhibit 1.1 hereto, and
the description of the terms of the underwriting agreement is
qualified in its entirety by reference to such exhibit. A copy of
the opinion of Cooley LLP relating to the legality of the
issuance and sale of the shares in the Offering is attached as
Exhibit 5.1 hereto.

On April6, 2017, the Registrant issued a press release announcing
the pricing of the Offering. A copy of this press release is
attached as Exhibit 99.1 hereto.

Neither the disclosures on this Current Report on Form 8-K nor
the attached press release shall constitute an offer to sell or
the solicitation of an offer to buy these securities, nor shall
there be any sale of these securities in any state or
jurisdiction in which such an offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.

About FibroGen, Inc. (NASDAQ:FGEN)

FibroGen, Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body’s natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies.

FibroGen, Inc. (NASDAQ:FGEN) Recent Trading Information

FibroGen, Inc. (NASDAQ:FGEN) closed its last trading session up +3.45 at 26.40 with 395,516 shares trading hands.